Xiao G - Search Results

1

Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.

Madorsky Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Olopade OI, Martini R, Stonaker B, Boateng R, Oppong JK, Adjei EK, Awuah B, Kyei I, Aitpillah FS, Adinku MO, Ankomah K, Osei-Bonsu EB, Gyan KK, Altorki NK, Cheng E, Ginter PS, Hoda S, Newman L, Elemento O, Davis MB, Martin ML, Bargonetti J. Madorsky Rowdo FP, et al. Among authors: xiao g. bioRxiv [Preprint]. 2023 Jun 22:2023.06.22.544406. doi: 10.1101/2023.06.22.544406. bioRxiv. 2023. PMID: 38076873 Free PMC article. Updated. Preprint.

2

p53 binds to a constitutively nucleosome free region of the mdm2 gene.

Xiao G, White D, Bargonetti J. Xiao G, et al. Oncogene. 1998 Mar 5;16(9):1171-81. doi: 10.1038/sj.onc.1201631. Oncogene. 1998. PMID: 9528859

3

A DNA damage signal is required for p53 to activate gadd45.

Xiao G, Chicas A, Olivier M, Taya Y, Tyagi S, Kramer FR, Bargonetti J. Xiao G, et al. Cancer Res. 2000 Mar 15;60(6):1711-9. Cancer Res. 2000. PMID: 10749144

4

Differential activation of p53 by the various adducts of mitomycin C.

Abbas T, Olivier M, Lopez J, Houser S, Xiao G, Kumar GS, Tomasz M, Bargonetti J. Abbas T, et al. Among authors: xiao g. J Biol Chem. 2002 Oct 25;277(43):40513-9. doi: 10.1074/jbc.M205495200. Epub 2002 Aug 14. J Biol Chem. 2002. PMID: 12183457 Free article.

5

Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction.

Xiao G, Kue P, Bhosle R, Bargonetti J. Xiao G, et al. Cell Cycle. 2015;14(5):744-54. doi: 10.1080/15384101.2014.997517. Cell Cycle. 2015. PMID: 25565400 Free PMC article.

6

Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.

Polotskaia A, Xiao G, Reynoso K, Martin C, Qiu WG, Hendrickson RC, Bargonetti J. Polotskaia A, et al. Among authors: xiao g. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1220-9. doi: 10.1073/pnas.1416318112. Epub 2015 Mar 2. Proc Natl Acad Sci U S A. 2015. PMID: 25733866 Free PMC article.

7

Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.

Qiu WG, Polotskaia A, Xiao G, Di L, Zhao Y, Hu W, Philip J, Hendrickson RC, Bargonetti J. Qiu WG, et al. Among authors: xiao g. NPJ Breast Cancer. 2017;3:1. doi: 10.1038/s41523-016-0001-7. Epub 2017 Jan 19. NPJ Breast Cancer. 2017. PMID: 28232952 Free PMC article.

8

Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.

Kundu N, Brekman A, Kim JY, Xiao G, Gao C, Bargonetti J. Kundu N, et al. Among authors: xiao g. Oncotarget. 2017 Jul 18;8(29):47916-47930. doi: 10.18632/oncotarget.18147. Oncotarget. 2017. PMID: 28615518 Free PMC article.

9

Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.

Gao C, Xiao G, Piersigilli A, Gou J, Ogunwobi O, Bargonetti J. Gao C, et al. Among authors: xiao g. Breast Cancer Res. 2019 Jan 14;21(1):5. doi: 10.1186/s13058-018-1094-8. Breast Cancer Res. 2019. PMID: 30642351 Free PMC article.

10

Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis.

Gao C, Xiao G, Bargonetti J. Gao C, et al. Among authors: xiao g. Oncotarget. 2019 Aug 20;10(49):5007-5010. doi: 10.18632/oncotarget.27134. eCollection 2019 Aug 20. Oncotarget. 2019. PMID: 31489110 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,361 results

Search Page